Equities Analysts Issue Forecasts for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Exelixis in a note issued to investors on Monday, March 3rd. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings per share of $0.35 for the quarter, down from their previous estimate of $0.40. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.50 EPS, FY2025 earnings at $1.92 EPS, Q1 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.47 EPS.

Several other brokerages also recently weighed in on EXEL. Barclays lifted their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Stephens reaffirmed an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. Piper Sandler boosted their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Finally, Wells Fargo & Company downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective on the stock. in a report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Stock Down 1.1 %

Shares of NASDAQ:EXEL opened at $38.21 on Thursday. The company has a market cap of $10.69 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 1.13 and a beta of 0.57. The firm’s 50-day simple moving average is $34.81 and its 200-day simple moving average is $31.91. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $39.30.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Insiders Place Their Bets

In other news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares of the company’s stock, valued at $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,343 shares of company stock worth $5,177,234. Insiders own 2.85% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Exelixis by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock valued at $979,994,000 after acquiring an additional 121,750 shares in the last quarter. LSV Asset Management raised its holdings in Exelixis by 0.8% in the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock valued at $272,056,000 after acquiring an additional 67,470 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in Exelixis by 10.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock valued at $254,110,000 after acquiring an additional 708,312 shares in the last quarter. Invesco Ltd. raised its holdings in Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after acquiring an additional 3,001,204 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Exelixis by 25.7% in the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock valued at $132,101,000 after acquiring an additional 810,857 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.